Consistently, DD01, a dual GLP-1/GCG RA, was evaluated in a phase 1 study, with promising results in hepatic steatosis by reducing LFC by ≥30%, which was assessed using MRI-PDFF. Here, GLP1R is linked to fatty liver disease.